Combination therapy with anti-mediator drugs in allergic disease
Combination therapy with anti-mediator drugs in allergic disease
Inflammatory mediators are local hormones that act via specific cell-surface receptors in an autocrine or paracrine manner to modulate the behaviour of inflammatory leucocytes and structural cells in inflamed tissues. The classical inflammatory mediators are the autacoids such as histamine, cysteinyl-leukotrienes (cys-LT), LTB4, prostanoids, bradykinin, and platelet-activating factor (PAF). Potent, selective, safe and long-acting compounds that inhibit the synthesis or block the receptors of individual autacoids have been developed over the last 20 years. The leukotriene (LT) modifiers (montelukast, pranlukast, zafirlukast, zileuton) have entered clinical practice for asthma, and the non-sedating H1 histamine antagonists (cetirizine, loratadine, terfenadine) are front-line therapies for allergic rhinitis and allergic skin disease. Potent inhibitors of prostanoid synthesis (NSAIDs) have been available for 100 years, but the new cycloxygenase-2-selective inhibitors (celecoxib, rofecoxib) may combat inflammation without the gastric and other adverse effects associated with traditional NSAIDs. Experimental antagonists of LTB4, PAF and the mast cell protease, tryptase, have also been investigated in clinical trials in asthma and other diseases, with mixed results.
11-17
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Rorke, S.
ca4b3d19-8862-40e7-8f33-b20da825b08d
2001
Sampson, A. P.
4ca76f6f-ff35-425d-a7e7-c2bd2ea2df60
Rorke, S.
ca4b3d19-8862-40e7-8f33-b20da825b08d
Sampson, A. P. and Rorke, S.
(2001)
Combination therapy with anti-mediator drugs in allergic disease.
Clinical and Experimental Allergy, 31 (1), .
(doi:10.1046/j.1365-2222.2001.01016.x).
Abstract
Inflammatory mediators are local hormones that act via specific cell-surface receptors in an autocrine or paracrine manner to modulate the behaviour of inflammatory leucocytes and structural cells in inflamed tissues. The classical inflammatory mediators are the autacoids such as histamine, cysteinyl-leukotrienes (cys-LT), LTB4, prostanoids, bradykinin, and platelet-activating factor (PAF). Potent, selective, safe and long-acting compounds that inhibit the synthesis or block the receptors of individual autacoids have been developed over the last 20 years. The leukotriene (LT) modifiers (montelukast, pranlukast, zafirlukast, zileuton) have entered clinical practice for asthma, and the non-sedating H1 histamine antagonists (cetirizine, loratadine, terfenadine) are front-line therapies for allergic rhinitis and allergic skin disease. Potent inhibitors of prostanoid synthesis (NSAIDs) have been available for 100 years, but the new cycloxygenase-2-selective inhibitors (celecoxib, rofecoxib) may combat inflammation without the gastric and other adverse effects associated with traditional NSAIDs. Experimental antagonists of LTB4, PAF and the mast cell protease, tryptase, have also been investigated in clinical trials in asthma and other diseases, with mixed results.
This record has no associated files available for download.
More information
Published date: 2001
Identifiers
Local EPrints ID: 455378
URI: http://eprints.soton.ac.uk/id/eprint/455378
ISSN: 0954-7894
PURE UUID: 7bac75d5-d54b-421c-9877-caade72bd335
Catalogue record
Date deposited: 18 Mar 2022 17:59
Last modified: 17 Mar 2024 02:43
Export record
Altmetrics
Contributors
Author:
S. Rorke
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
